| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Tenofovir | 7 | 2019 | 449 | 0.59 | Why? |
| HIV Infections | 23 | 2020 | 11620 | 0.58 | Why? |
| Switzerland | 18 | 2020 | 2738 | 0.51 | Why? |
| Anti-HIV Agents | 10 | 2019 | 2209 | 0.48 | Why? |
| Respiratory System | 2 | 2020 | 3213 | 0.43 | Why? |
| Antiretroviral Therapy, Highly Active | 5 | 2017 | 952 | 0.32 | Why? |
| Coinfection | 5 | 2020 | 6820 | 0.31 | Why? |
| HIV-1 | 8 | 2020 | 3365 | 0.30 | Why? |
| Adenine | 3 | 2019 | 463 | 0.30 | Why? |
| Virus Shedding | 3 | 2020 | 5834 | 0.29 | Why? |
| Liver Transplantation | 1 | 2020 | 2864 | 0.27 | Why? |
| Interleukins | 3 | 2018 | 762 | 0.26 | Why? |
| CD4 Lymphocyte Count | 5 | 2019 | 1517 | 0.24 | Why? |
| HIV Antibodies | 2 | 2018 | 776 | 0.23 | Why? |
| Hepatitis B virus | 3 | 2019 | 882 | 0.22 | Why? |
| Hepatitis C, Chronic | 4 | 2019 | 973 | 0.22 | Why? |
| Anti-Retroviral Agents | 3 | 2018 | 1099 | 0.21 | Why? |
| Critical Illness | 3 | 2020 | 17281 | 0.21 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2020 | 6166 | 0.19 | Why? |
| Hepatitis B | 2 | 2019 | 888 | 0.19 | Why? |
| HLA-B Antigens | 1 | 2019 | 166 | 0.18 | Why? |
| Extraintestinal Pathogenic Escherichia coli | 1 | 2017 | 6 | 0.18 | Why? |
| HLA-C Antigens | 1 | 2019 | 195 | 0.17 | Why? |
| Escherichia coli Vaccines | 1 | 2017 | 7 | 0.17 | Why? |
| Pain, Intractable | 1 | 2017 | 7 | 0.17 | Why? |
| HLA-A Antigens | 1 | 2019 | 196 | 0.17 | Why? |
| Sarcoma, Kaposi | 1 | 2018 | 97 | 0.17 | Why? |
| Rilpivirine | 1 | 2017 | 65 | 0.17 | Why? |
| Hepatitis Delta Virus | 1 | 2017 | 54 | 0.17 | Why? |
| Organophosphonates | 2 | 2008 | 85 | 0.17 | Why? |
| Hepatitis D | 1 | 2017 | 48 | 0.17 | Why? |
| Immune Reconstitution | 1 | 2017 | 48 | 0.16 | Why? |
| Raltegravir Potassium | 1 | 2017 | 132 | 0.16 | Why? |
| Emtricitabine | 1 | 2017 | 202 | 0.16 | Why? |
| Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 176 | 0.16 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2019 | 260 | 0.16 | Why? |
| Neck Pain | 1 | 2017 | 126 | 0.15 | Why? |
| Epitope Mapping | 1 | 2020 | 1240 | 0.15 | Why? |
| Yellow Fever | 1 | 2018 | 231 | 0.14 | Why? |
| Alanine | 3 | 2021 | 5687 | 0.14 | Why? |
| HIV | 2 | 2019 | 1116 | 0.14 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2017 | 275 | 0.14 | Why? |
| Genetic Predisposition to Disease | 2 | 2019 | 4027 | 0.13 | Why? |
| Genotype | 6 | 2018 | 4697 | 0.13 | Why? |
| Adenosine Monophosphate | 2 | 2021 | 5652 | 0.13 | Why? |
| Insurance, Health | 1 | 2019 | 634 | 0.13 | Why? |
| Syphilis | 1 | 2017 | 318 | 0.12 | Why? |
| Antiviral Agents | 6 | 2021 | 41703 | 0.12 | Why? |
| Thorax | 1 | 2021 | 1873 | 0.11 | Why? |
| Urinary Tract Infections | 1 | 2017 | 534 | 0.11 | Why? |
| Prospective Studies | 10 | 2020 | 43301 | 0.10 | Why? |
| Health Care Costs | 1 | 2019 | 1007 | 0.10 | Why? |
| Antimicrobial Stewardship | 1 | 2018 | 931 | 0.10 | Why? |
| Hepacivirus | 3 | 2017 | 1509 | 0.10 | Why? |
| Interferons | 3 | 2018 | 2885 | 0.10 | Why? |
| Comorbidity | 5 | 2020 | 34796 | 0.09 | Why? |
| Antibodies, Neutralizing | 4 | 2020 | 25288 | 0.09 | Why? |
| Carcinoma, Hepatocellular | 1 | 2019 | 1222 | 0.09 | Why? |
| Middle Aged | 24 | 2021 | 270681 | 0.09 | Why? |
| Viral Load | 6 | 2020 | 15850 | 0.09 | Why? |
| Papillomavirus Infections | 1 | 2017 | 861 | 0.09 | Why? |
| Drug Interactions | 2 | 2019 | 1653 | 0.09 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1573 | 0.09 | Why? |
| Mothers | 1 | 2018 | 1624 | 0.09 | Why? |
| Antibody Formation | 2 | 2018 | 4038 | 0.08 | Why? |
| Breast Feeding | 1 | 2018 | 1585 | 0.08 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.08 | Why? |
| Anti-Bacterial Agents | 2 | 2020 | 10083 | 0.08 | Why? |
| Liver Neoplasms | 1 | 2019 | 1666 | 0.08 | Why? |
| Polypharmacy | 1 | 2010 | 347 | 0.08 | Why? |
| Male | 25 | 2020 | 367725 | 0.08 | Why? |
| Liver Cirrhosis | 1 | 2017 | 1810 | 0.07 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.07 | Why? |
| Humans | 39 | 2021 | 930598 | 0.07 | Why? |
| Health Resources | 1 | 2019 | 2592 | 0.07 | Why? |
| Female | 27 | 2021 | 380317 | 0.07 | Why? |
| Cohort Studies | 10 | 2020 | 36005 | 0.07 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.07 | Why? |
| Hepatitis C | 1 | 2017 | 1514 | 0.07 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.07 | Why? |
| Point Mutation | 1 | 2008 | 481 | 0.07 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.07 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.07 | Why? |
| Liver Diseases | 1 | 2020 | 2698 | 0.07 | Why? |
| Homosexuality, Male | 3 | 2018 | 1158 | 0.07 | Why? |
| Decision Making | 1 | 2018 | 3132 | 0.07 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.06 | Why? |
| Specimen Handling | 1 | 2020 | 6190 | 0.06 | Why? |
| Genome-Wide Association Study | 1 | 2010 | 1648 | 0.06 | Why? |
| Methicillin Resistance | 1 | 2002 | 77 | 0.06 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2018 | 3607 | 0.06 | Why? |
| Palliative Care | 1 | 2017 | 2665 | 0.06 | Why? |
| Communicable Diseases | 1 | 2017 | 2148 | 0.06 | Why? |
| Ambulatory Care | 1 | 2019 | 4947 | 0.06 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.06 | Why? |
| Adult | 19 | 2019 | 244371 | 0.05 | Why? |
| Glomerular Filtration Rate | 1 | 2007 | 1262 | 0.05 | Why? |
| Medical Oncology | 1 | 2017 | 3826 | 0.05 | Why? |
| Risk Factors | 5 | 2020 | 71621 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.05 | Why? |
| Aged | 12 | 2020 | 215776 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.05 | Why? |
| Protein Structure, Quaternary | 1 | 2020 | 455 | 0.05 | Why? |
| Vincristine | 1 | 2018 | 89 | 0.05 | Why? |
| Antigen-Antibody Reactions | 1 | 2020 | 616 | 0.05 | Why? |
| Diabetes Mellitus | 1 | 2020 | 8207 | 0.04 | Why? |
| Pandemics | 6 | 2020 | 389249 | 0.04 | Why? |
| Antibodies, Monoclonal, Murine-Derived | 1 | 2018 | 94 | 0.04 | Why? |
| Equivalence Trials as Topic | 1 | 2018 | 242 | 0.04 | Why? |
| Protective Agents | 1 | 2020 | 250 | 0.04 | Why? |
| Alkynes | 1 | 2017 | 98 | 0.04 | Why? |
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2018 | 95 | 0.04 | Why? |
| Immunoglobulin G | 2 | 2020 | 21571 | 0.04 | Why? |
| Clinical Audit | 1 | 2018 | 204 | 0.04 | Why? |
| Benzoxazines | 1 | 2017 | 103 | 0.04 | Why? |
| Nevirapine | 1 | 2017 | 57 | 0.04 | Why? |
| Hepatitis B Surface Antigens | 1 | 2019 | 305 | 0.04 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.04 | Why? |
| Prognosis | 1 | 2020 | 32490 | 0.04 | Why? |
| Computers | 1 | 2018 | 199 | 0.04 | Why? |
| Radiation Dosage | 1 | 2021 | 585 | 0.04 | Why? |
| Viral Vaccines | 1 | 2018 | 7560 | 0.04 | Why? |
| Self Report | 2 | 2020 | 3802 | 0.04 | Why? |
| Cyclophosphamide | 1 | 2018 | 387 | 0.04 | Why? |
| Exercise | 1 | 2017 | 6771 | 0.04 | Why? |
| Administration, Intravenous | 1 | 2020 | 1115 | 0.04 | Why? |
| Feedback | 1 | 2018 | 317 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Doxorubicin | 1 | 2018 | 313 | 0.04 | Why? |
| Unsafe Sex | 1 | 2017 | 139 | 0.04 | Why? |
| Oxazines | 1 | 2017 | 279 | 0.04 | Why? |
| Heterosexuality | 1 | 2017 | 148 | 0.04 | Why? |
| Italy | 1 | 2020 | 38444 | 0.04 | Why? |
| Incidence | 4 | 2019 | 25622 | 0.04 | Why? |
| Virus Replication | 1 | 2017 | 14331 | 0.04 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.04 | Why? |
| Sustained Virologic Response | 1 | 2017 | 378 | 0.04 | Why? |
| Staphylococcus aureus | 1 | 2002 | 844 | 0.04 | Why? |
| Cyclopropanes | 1 | 2017 | 332 | 0.04 | Why? |
| env Gene Products, Human Immunodeficiency Virus | 1 | 2018 | 386 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2021 | 25144 | 0.03 | Why? |
| Mental Disorders | 1 | 2017 | 6742 | 0.03 | Why? |
| Piperazines | 1 | 2017 | 445 | 0.03 | Why? |
| Developed Countries | 1 | 2018 | 500 | 0.03 | Why? |
| Prednisone | 1 | 2018 | 652 | 0.03 | Why? |
| Lamivudine | 1 | 2015 | 210 | 0.03 | Why? |
| AIDS Vaccines | 1 | 2018 | 452 | 0.03 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2020 | 2324 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2018 | 1654 | 0.03 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.03 | Why? |
| Single-Blind Method | 1 | 2017 | 1283 | 0.03 | Why? |
| Protein Binding | 2 | 2020 | 11430 | 0.03 | Why? |
| Staphylococcal Infections | 1 | 2002 | 1099 | 0.03 | Why? |
| Kidney | 1 | 2007 | 3648 | 0.03 | Why? |
| Treatment Outcome | 4 | 2021 | 51732 | 0.03 | Why? |
| Substance Abuse, Intravenous | 1 | 2017 | 411 | 0.03 | Why? |
| Kinetics | 1 | 2020 | 3238 | 0.03 | Why? |
| Immunogenicity, Vaccine | 2 | 2018 | 4624 | 0.03 | Why? |
| Pyridones | 1 | 2017 | 738 | 0.03 | Why? |
| Withholding Treatment | 1 | 2017 | 798 | 0.03 | Why? |
| Lung | 1 | 2020 | 31049 | 0.03 | Why? |
| Demography | 1 | 2018 | 1660 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2018 | 2437 | 0.03 | Why? |
| Seroepidemiologic Studies | 2 | 2017 | 10017 | 0.03 | Why? |
| Antibodies, Viral | 3 | 2020 | 51949 | 0.03 | Why? |
| Decision Support Techniques | 1 | 2018 | 903 | 0.03 | Why? |
| Immunization Schedule | 1 | 2018 | 1305 | 0.03 | Why? |
| Remission, Spontaneous | 1 | 2011 | 186 | 0.03 | Why? |
| Morbidity | 1 | 2017 | 1426 | 0.03 | Why? |
| Virulence | 1 | 2018 | 2172 | 0.03 | Why? |
| Regression Analysis | 1 | 2018 | 2484 | 0.03 | Why? |
| Rituximab | 1 | 2018 | 1096 | 0.03 | Why? |
| Hepatitis B, Chronic | 1 | 2017 | 616 | 0.03 | Why? |
| Drug Therapy, Combination | 2 | 2017 | 7268 | 0.03 | Why? |
| Central Nervous System Agents | 1 | 2010 | 45 | 0.03 | Why? |
| Immunization, Secondary | 1 | 2018 | 1649 | 0.03 | Why? |
| Follow-Up Studies | 2 | 2019 | 17020 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.02 | Why? |
| Viremia | 1 | 2017 | 1020 | 0.02 | Why? |
| Sex Distribution | 1 | 2017 | 2083 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.02 | Why? |
| Drug Resistance, Viral | 1 | 2015 | 1083 | 0.02 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.02 | Why? |
| HIV Reverse Transcriptase | 1 | 2008 | 104 | 0.02 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2010 | 309 | 0.02 | Why? |
| Epitopes | 1 | 2020 | 4113 | 0.02 | Why? |
| Early Diagnosis | 1 | 2017 | 2443 | 0.02 | Why? |
| Binding Sites | 1 | 2020 | 6201 | 0.02 | Why? |
| Drug Combinations | 1 | 2017 | 3852 | 0.02 | Why? |
| Protein Domains | 1 | 2020 | 6563 | 0.02 | Why? |
| Molecular Dynamics Simulation | 1 | 2020 | 4155 | 0.02 | Why? |
| Survival Analysis | 1 | 2020 | 7592 | 0.02 | Why? |
| Age Distribution | 1 | 2017 | 3567 | 0.02 | Why? |
| Methadone | 1 | 2010 | 296 | 0.02 | Why? |
| Phenotype | 1 | 2018 | 4037 | 0.02 | Why? |
| Genetic Variation | 2 | 2011 | 3919 | 0.02 | Why? |
| HIV Protease Inhibitors | 1 | 2010 | 434 | 0.02 | Why? |
| Haplotypes | 1 | 2010 | 853 | 0.02 | Why? |
| Aged, 80 and over | 4 | 2020 | 88759 | 0.02 | Why? |
| Polyethylene Glycols | 1 | 2010 | 574 | 0.02 | Why? |
| Renin-Angiotensin System | 1 | 2020 | 3661 | 0.02 | Why? |
| Electronic Health Records | 1 | 2018 | 3492 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| France | 1 | 2020 | 12074 | 0.02 | Why? |
| Survival Rate | 1 | 2018 | 9206 | 0.02 | Why? |
| Treatment Failure | 1 | 2010 | 2106 | 0.02 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.02 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2018 | 4545 | 0.02 | Why? |
| Ribavirin | 1 | 2010 | 1182 | 0.02 | Why? |
| RNA, Viral | 2 | 2020 | 32276 | 0.01 | Why? |
| Interferon-alpha | 1 | 2010 | 1442 | 0.01 | Why? |
| Prevalence | 2 | 2017 | 25773 | 0.01 | Why? |
| Young Adult | 3 | 2017 | 93724 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2020 | 8041 | 0.01 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2018 | 5164 | 0.01 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.01 | Why? |
| Mortality | 1 | 2017 | 7132 | 0.01 | Why? |
| Primary Health Care | 1 | 2018 | 4839 | 0.01 | Why? |
| Adolescent | 3 | 2018 | 86841 | 0.01 | Why? |
| Recombinant Proteins | 1 | 2010 | 3786 | 0.01 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.01 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.01 | Why? |
| Phylogeny | 1 | 2018 | 13341 | 0.01 | Why? |
| Pregnancy | 1 | 2018 | 23879 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Logistic Models | 1 | 2008 | 9089 | 0.01 | Why? |
| Vaccination | 1 | 2017 | 19050 | 0.01 | Why? |
| Health Surveys | 1 | 2002 | 2841 | 0.01 | Why? |
| Retrospective Studies | 1 | 2015 | 105322 | 0.00 | Why? |
| Infant | 1 | 2002 | 30274 | 0.00 | Why? |
| Child, Preschool | 1 | 2002 | 36283 | 0.00 | Why? |
| Child | 1 | 2002 | 70012 | 0.00 | Why? |